Compare
Elicio Therapeutics, Inc. vs BeyondSpring Inc. vs CASI Pharmaceuticals, Inc. vs Onconetix, Inc.
| Latest fiscal year | Elicio Therapeutics, Inc. ELTX | BeyondSpring Inc. BYSI | CASI Pharmaceuticals, Inc. CASIF | Onconetix, Inc. ONCO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $20.71M | $815.4K |
| Revenue growth (YoY) | n/a | n/a | -27.4% | -67.7% |
| Gross margin | n/a | n/a | 48.6% | 77.6% |
| Operating margin | n/a | n/a | -217.3% | n/m |
| Net margin | n/a | n/a | -232.0% | n/m |
| Net income | -$39.57M | -$1.01M | -$48.06M | -$14.03M |
| EPS (Diluted) | -$2.58 | n/a | -$2.59 | -$16.56 |
| Operating cash flow | -$36.95M | -$19.77M | -$20.75M | -$9.68M |
| Free cash flow | -$36.97M | -$19.82M | -$20.77M | n/a |
| Cash & equivalents | $18.56M | $7.79M | $5.63M | n/a |
| Total assets | $25.86M | $25.93M | $25.65M | $24.93M |
| Total liabilities | $24.23M | $49.92M | $62.93M | $9.16M |
| Shareholders' equity | $1.64M | -$23.99M | -$37.28M | $15.76M |
| Return on year-end equity | n/m | n/a | n/a | -89.0% |
| Shares outstanding | 17.80M | n/a | 20.56M | 1.56M |
Revenue, most recent five fiscal years
| Fiscal year | Elicio Therapeutics, Inc. | BeyondSpring Inc. | CASI Pharmaceuticals, Inc. | Onconetix, Inc. |
|---|---|---|---|---|
| Latest | $2.30M Ended 2022-12-31 | $0 Ended 2025-12-31 | $20.71M Ended 2025-12-31 | $815.4K Ended 2025-12-31 |
| 1 year earlier | $28.31M Ended 2021-12-31 | $0 Ended 2024-12-31 | $28.54M Ended 2024-12-31 | $2.52M Ended 2024-12-31 |
| 2 years earlier | $2.88M Ended 2020-12-31 | $0 Ended 2023-12-31 | $33.88M Ended 2023-12-31 | $58.5K Ended 2023-12-31 |
| 3 years earlier | n/a | $1.35M Ended 2022-12-31 | $43.11M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $1.35M Ended 2021-12-31 | $30.17M Ended 2021-12-31 | n/a |